Investigational antiviral therapies for the treatment of influenza.

Abstract:

INTRODUCTION:Influenza viral ribonucleoprotein complexes (vRNPs) play a key role in viral transcription and replication; hence, the recent development of novel anti-influenza drugs targeting vRNPs has garnered widespread interest. AREAS COVERED:We discuss the function of the constituents of vRNPs and summarize those vRNPs-targeted synthetic drugs that are in preclinical and early clinical development. EXPERT OPINION:vRNPs contain high-value drug targets; such targets include the subunits PA, PB1, PB2, and NP. Developing a new generation of antiviral therapies with strategies that utilize existing drugs, natural compounds originated from new resources and novel drug combinations may open up new therapeutic approaches to influenza.

authors

Yang J,Huang Y,Liu S

doi

10.1080/13543784.2019.1606210

subject

Has Abstract

pub_date

2019-05-01 00:00:00

pages

481-488

issue

5

eissn

1354-3784

issn

1744-7658

journal_volume

28

pub_type

杂志文章,评审
  • Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators.

    abstract::CGRP is a potent vasodilator that has been shown to have a physiological and/or pathological role in neurogenic inflammation, headaches including migraine, thermal injury, circulatory shock, pregnancy and menopause, hypertension and heart failure and is known to be cardioprotective. CGRP is also a positive inotrope an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.6.1131

    authors: Doggrell SA

    更新日期:2001-06-01 00:00:00

  • Developments with experimental and investigational drugs for axial spondyloarthritis.

    abstract:INTRODUCTION:Axial spondyloarthritis (AxS pA) is a chronic inflammatory disease for which, until recently, there were no valid therapeutic alternatives to TNF-α blocking agents. This unmet clinical need led to explore several therapeutic targets, from proinflammatory cytokines to intracellular signaling systems. The re...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1337744

    authors: Clavel G,Boissier MC,Sigaux J,Semerano L

    更新日期:2017-07-01 00:00:00

  • Ticagrelor for the treatment of peripheral arterial disease.

    abstract:INTRODUCTION:Peripheral arterial disease (PAD) is a manifestation, and marker of severity, of a generalized atherosclerotic process. Antiplatelet therapy is recommended to prevent cardiovascular events but much of the evidence to support this is drawn from studies on older drugs. AREAS COVERED:In this review, the auth...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.974803

    authors: Chong AY,So DY

    更新日期:2014-12-01 00:00:00

  • Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.

    abstract:INTRODUCTION:The introduction and exploration of novel agents has significantly improved patient outcome in the treatment of multiple myeloma (MM). One such compound, bortezomib, was the first proteasome inhibitor (PI) to be approved as a MM therapeutic. The efficacy and safety data provided by bortezomib usage has pro...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.920821

    authors: Bringhen S,Gay F,Donato F,Troia R,Mina R,Palumbo A

    更新日期:2014-09-01 00:00:00

  • Ganetespib for small cell lung cancer.

    abstract:INTRODUCTION:Heat shock proteins (Hsps) are part of a complex network of chaperone proteins that are critically involved in the conformational maturation of intracellular proteins and regulate their degradation via the proteasome system Hsps (especially Hsp70 and Hsp90) are upregulated in many cancers and are potential...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1268599

    authors: Subramaniam DS,Warner EA,Giaccone G

    更新日期:2017-01-01 00:00:00

  • Biological versatility of crotamine--a cationic peptide from the venom of a South American rattlesnake.

    abstract:IMPORTANCE OF THE FIELD:Molecules isolated from animals, insects, plants or microorganisms can provide prototypes for design of biopharmaceutical products. Some venom toxins and their derivatives are used in medicine, while others provide templates for development of new drugs. AREAS COVERED IN THIS REVIEW:The mild to...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.534457

    authors: Kerkis I,Silva Fde S,Pereira A,Kerkis A,Rádis-Baptista G

    更新日期:2010-12-01 00:00:00

  • Insulin glargine: the first clinically useful extended-acting insulin in half a century?

    abstract::Insulin glargine (HOE 901) appears to be the first clinically useful extended-acting insulin preparation for 50 years. A combination of a di-arginine addition to the C-terminal of the insulin B-chain, and a glycine substitution in the A-chain, produce an insulin which is soluble at acid pH, but precipitates in sc. tis...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.8.3.307

    authors: Home P

    更新日期:1999-03-01 00:00:00

  • Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.

    abstract::This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.12.2903

    authors: Kelland LR

    更新日期:2000-12-01 00:00:00

  • Ixabepilone for the treatment of solid tumors: a review of clinical data.

    abstract:BACKGROUND:Microtubule stabilizing agents such as taxanes are an integral part of therapy for multiple solid tumors. However, due to limitations of these agents, newer more effective cytotoxic agents are necessary. Ixabepilone, an epothilone B analog, is a novel microtubule stabilizing agent. OBJECTIVE:This review pro...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.3.423

    authors: Denduluri N,Swain SM

    更新日期:2008-03-01 00:00:00

  • Drug delivery across the skin.

    abstract::Since the introduction of the first through the skin (TTS) therapeutic in 1980, a total of 34 TTS products have been marketed and numerous drugs have been tested by more than 50 commercial organisations for their suitability for TTS delivery. Most of the agents which have been tested have had low molecular weights, du...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.12.1887

    authors: Cevc G

    更新日期:1997-12-01 00:00:00

  • Therapeutic potential of the bactericidal/permeability-increasing protein.

    abstract::Innate immune mechanisms respond rapidly to bacterial infection. A key cellular component of the innate immune response is the neutrophil, whose cytoplasmic granules contain a variety of antimicrobial proteins and peptides. Among these is the bactericidal/permeability-increasing protein (BPI), a cationic 55 kDa protei...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.2.159

    authors: Levy O

    更新日期:2002-02-01 00:00:00

  • Lenalidomide for the treatment of B-cell lymphoma.

    abstract:INTRODUCTION:Although the combination of an anti-CD20 monoclonal antibody and chemotherapy has widely improved survival of patients with B-cell lymphoma, the disease still relapses. A better understanding of the biology of lymphomas has highlighted the role of the cell of origin in response to treatment and outcome. Le...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1208170

    authors: Garciaz S,Coso D,Schiano de Colella JM,Bouabdallah R

    更新日期:2016-09-01 00:00:00

  • Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.

    abstract::This paper reviews the clinical pharmacology, efficacy and safety of the novel antipsychotic drug aripiprazole. All published citations regarding aripiprazole were reviewed using a Medline((R)) search (completed for citations through mid-year, 2002). In addition, abstracts from recent scientific meetings presenting da...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.4.655

    authors: Keck PE Jr,McElroy SL

    更新日期:2003-04-01 00:00:00

  • Immunoadsorption, current status and future developments.

    abstract::The association of abnormalities in the cellular and humoral immune system with various autoimmune diseases provides the rationale for apheresis technologies. While plasmapheresis or plasma exchange is limited by its non-selective removal of all plasma components, modern apheresis techniques aim to provide more specif...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.9.2017

    authors: Braun N,Bosch T

    更新日期:2000-09-01 00:00:00

  • Investigational drugs for visceral leishmaniasis.

    abstract::Introduction: The armamentarium of antileishmanial drugs is small. It is further being threatened by the development of resistance and decreasing sensitivity to the available drugs. The development of newer drugs is sorely needed. Areas covered: The authors have based their review on a literature search performed usin...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.2014.954035

    authors: Sundar S,Chakravarty J

    更新日期:2015-01-01 00:00:00

  • Toll-like receptor modulation in cardiovascular disease: a target for intervention?

    abstract::Toll-like receptors (TLRs) form a family of pattern recognition receptors that have emerged as key mediators of innate immunity. These receptors sense invading microbes and initiate the immune response. TLR-mediated inflammation is an important pathogenic link between innate immunity and a diverse panel of clinical di...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.8.857

    authors: Földes G,von Haehling S,Anker SD

    更新日期:2006-08-01 00:00:00

  • Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options.

    abstract:BACKGROUND:Peritoneal carcinomatosis (PC) is a challenging consequence of certain malignancies, associated with a poor prognosis and limited treatment options. Generally, PC has been treated similarly to metastatic cancers of the primary tumor, but associated with worse outcomes when compared to other sites of metastat...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780902939151

    authors: Davies JM,O'Neil B

    更新日期:2009-07-01 00:00:00

  • Regorafenib for cancer.

    abstract:INTRODUCTION:Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-β, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase. AREAS COVERED:This review covers the preclinical development of regorafenib as well as the pivotal Phase I studies. The safety profile of...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.684752

    authors: Strumberg D,Schultheis B

    更新日期:2012-06-01 00:00:00

  • Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition.

    abstract:INTRODUCTION:Cardiovascular disease is the leading cause of death worldwide, accounting for 30% of all deaths, with elevated blood pressure probably the most important modifiable risk factor. Worldwide, elevated blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all annual deaths. New ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.797962

    authors: Segura J,Salazar J,Ruilope LM

    更新日期:2013-07-01 00:00:00

  • Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.

    abstract::Inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) has an established role in the treatment of advanced non-small cell lung cancer. The first-generation EGFR inhibitors erlotinib and gefitinib have been approved for treatment in the second- and third-line setting. Second-generation ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780902762843

    authors: Mukherji D,Spicer J

    更新日期:2009-03-01 00:00:00

  • GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.

    abstract:INTRODUCTION:The N-methyl-d-aspartate receptor-ionophore complex plays a key role in learning and memory and has efficacy in animals and humans with affective disorders. GLYX-13 is an N-methyl-d-aspartate receptor (NMDAR) glycine-site functional partial agonist and cognitive enhancer that also shows rapid antidepressan...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.852536

    authors: Moskal JR,Burch R,Burgdorf JS,Kroes RA,Stanton PK,Disterhoft JF,Leander JD

    更新日期:2014-02-01 00:00:00

  • Effects of ADP-receptor antagonism beyond traditional inhibition of platelet aggregation.

    abstract::Atherothrombosis, or thrombus formation, at the site of a disrupted atherosclerotic plaque is the common pathophysiology related to myocardial infarction, ischaemic stroke and peripheral arterial disease. A growing body of evidence demonstrates an important role for vascular inflammation in the pathophysiology of athe...

    journal_title:Expert opinion on investigational drugs

    pub_type: 社论

    doi:10.1517/13543784.13.5.457

    authors: Herbert JM

    更新日期:2004-05-01 00:00:00

  • 153Sm: its use in multiple myeloma and report of a clinical experience.

    abstract:BACKGROUND:In the past years the bone seeking radiopharmaceutical samarium lexidronam ((153)Sm-EDTMP) has been increasingly used alone or in conjunction with chemotherapy and/or bisphosphonates for the treatment of painful bone metastasis. OBJECTIVE:Its use has been explored in different solid tumours. In this report ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.17.9.1379

    authors: Abruzzese E,Iuliano F,Trawinska MM,Di Maio M

    更新日期:2008-09-01 00:00:00

  • Tirofiban: an investigational platelet glycoprotein IIb/IIIa receptor antagonist.

    abstract::The deposition of a platelet rich thrombus on an atherosclerotic plaque is a critical step in the development of unstable coronary syndromes. Currently available therapeutic agents such as aspirin and ticlopidine are relatively weak inhibitors of platelet aggregation. Recently, antagonists to platelet glycoprotein IIb...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.9.1257

    authors: Kumar A,Herrmann HC

    更新日期:1997-09-01 00:00:00

  • Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use.

    abstract::Effectiveness of the influenza vaccine in persons with high-risk conditions needs to be improved. In this paper, the authors review various vaccination strategies, including repeated doses of the vaccine or the use of higher hemagglutinin (HA) content vaccines that have been shown to result in improved immunogenicity....

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.7.927

    authors: Safdar A,Cox MM

    更新日期:2007-07-01 00:00:00

  • Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development.

    abstract::This review highlights some important advances that have taken place in cannabinoid research over the last four years. It focuses on novel ligands that are of interest either as experimental tools or as lead compounds for therapeutic agents and possible clinical applications for some of these ligands. The molecular ta...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.7.1553

    authors: Pertwee RG

    更新日期:2000-07-01 00:00:00

  • Aripiprazole acts as a selective dopamine D2 receptor partial agonist.

    abstract::Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.6.771

    authors: Wood M,Reavill C

    更新日期:2007-06-01 00:00:00

  • Asimadoline in the treatment of irritable bowel syndrome.

    abstract:IMPORTANCE OF THE FIELD:Irritable bowel syndrome (IBS) represents one of the most common gastrointestinal disorders, with the diarrhea-predominant form (D-IBS) representing an area of high unmet medical need. One difficulty in identifying suitable treatments for IBS is that although there are animal models for the comp...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.515209

    authors: Mangel AW,Williams VS

    更新日期:2010-10-01 00:00:00

  • A novel CXCR4 antagonist for hematopoietic stem cell mobilization.

    abstract:BACKGROUND:Hematopoietic stem cell (HSC) transplantation is a treatment option for hematological malignancies. Current mobilization regimes frequently result in inadequate numbers of HSC for transplant therefore alternative methods of mobilization are required. OBJECTIVE:The chemokine receptor CXCR4 and ligand SDF-1 a...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.11.1749

    authors: Fricker SP

    更新日期:2008-11-01 00:00:00

  • The therapeutic potential of monoclonal antibodies against respiratory syncytial virus.

    abstract::Attempts to develop a vaccine against respiratory syncytial virus (RSV), the major cause of lower respiratory tract disease in infants and young children, have been unsuccessful. Passive immunisation with antibody to RSV has been found to be an effective alternative method for prophylaxis. The product currently in use...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.8.1271

    authors: Weltzin R

    更新日期:1998-08-01 00:00:00